Anti-diabetic actions of carbon monoxide-releasing molecule (CORM)-A1: Immunomodulation and regeneration of islet beta cells

Immunology Letters

Volumn 165, Issue 1, 2015, Pages 39-46

  Nikolic, Ivana ^a   Saksida, Tamara ^a   Vujicic, Milica ^a   Stojanovic, Ivana ^a   Stosic Grujicic, Stanislava ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Carbon monoxide releasing molecule A1; Cytokines; Islets of Langerhans; Lymphocytes; Type 1 diabetes

Indexed keywords

ANTIDIABETIC AGENT; CARBON MONOXIDE RELEASING MOLECULE A1; CYCLOPHOSPHAMIDE; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR ALPHA; KI 67 ANTIGEN; MESSENGER RNA; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; BORANE DERIVATIVE; CARBONIC ACID DERIVATIVE; CYTOKINE; IMMUNOLOGIC FACTOR; SODIUM BORANOCARBONATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; BIOLOGICAL MONITORING; CELL REGENERATION; CONTROLLED STUDY; EX VIVO STUDY; FOXP3+ REGULATORY T LYMPHOCYTE; GENE EXPRESSION; HYPERGLYCEMIA; IMMUNOMODULATION; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; LYMPH NODE CELL; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREATIC LYMPH NODE CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SPLEEN CELL; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TREATMENT DURATION; UPREGULATION; ANIMAL; BIOSYNTHESIS; DIABETES MELLITUS, TYPE 1; DISEASE MODEL; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; BORANES; CARBONATES; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; HYPOGLYCEMIC AGENTS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; INSULIN-SECRETING CELLS; MALE; MICE; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 84926432165     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2015.03.009     Document Type: Article

References (41)

1. Bluestone J.A., Herold K., Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 2010, 464:1293-1300.
2. van Belle T.L., Coppieters K.T., von Herrath M.G. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol. Rev. 2011, 91:79-118.
3. Rabinovitch A. An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus. Diabetes Metab. Rev. 1998, 14:129-151.
4. Santana M.A., Rosenstein Y. What it takes to become an effector T cell: the process, the cells involved, and the mechanisms. J. Cell. Physiol. 2003, 195:392.
5. Wraith D.C., Nicolson K.S., Whitley N.T. Regulatory CD4+T cells and the control of autoimmune disease. Curr. Opin. Immunol. 2004, 16:695-701.
6. Bonner-Weir S., Li W.C., Ouziel-Yahalom L., Guo L., Weir G.C., Sharma A. Beta-cell growth and regeneration: replication is only part of the story. Diabetes 2010, 59:2340-2348.
7. Nepom G.T., Ehlers M., Mandrup-Poulsen T. Anti-cytokine therapies in T1D: concepts and strategies. Clin. Immunol. 2013, 149:279-285.
8. Mezza T., Kulkarni R.N. The regulation of pre- and post-maturational plasticity of mammalian islet cell mass. Diabetologia 2014, 57:1291-1303.
9. Motterlini R., Sawle P., Hammad J., Bains S., Alberto R., Foresti R., et al. CORM-A1: a new pharmacologically active carbon monoxide-releasing molecule. FASEB J 2005, 19:284-286.
10. Foresti R., Bani-Hani M.G., Motterlini R. Use of carbon monoxide as a therapeutic agent: promises and challenges. Intensive Care Med. 2008, 34:649-658.
11. Motterlini R., Mann B.E., Foresti R. Therapeutic applications of carbon monoxide-releasing molecules (CO-RMs). Expert Opin. Investig. Drugs 2005, 14:1305-1318.
12. Motterlini R. Carbon monoxide-releasing molecules (CO-RMs): vasodilatory, anti-ischaemic and anti-inflammatory activities. Biochem. Soc. Trans. 2007, 35:1142-1146.
13. Fagone P., Mangano K., Quattrocchi C., Motterlini R., Di Marco R., Magro G., et al. Prevention of clinical and histological signs of proteolipid protein (PLP)-induced experimental allergic encephalomyelitis (EAE) in mice by the water-soluble carbon monoxide-releasing molecule (CORM)-A1. Clin. Exp. Immunol. 2011, 163:368-374.
14. Hosick P.A., AlAmodi A.A., Storm M.V., Gousset M.U., Pruett B.E., Gray W, et al. Chronic carbon monoxide treatment attenuates development of obesity and remodels adipocytes in mice fed a high-fat diet. Int. J. Obes. (Lond.) 2014, 38:132-139.
15. Bakhautdin B., Das D., Mandal P., Roychowdhury S., Danner J., Bush K., et al. Protective role of HO-1 and carbon monoxide in ethanol-induced cell death in hepatocytes and liver injury in mice. J. Hepatol. 2014, (pii: S0168-8278(14)00402-4). 10.1016/j.jhep.2014.06.007.
16. Nikolic I., Saksida T., Mangano K., Vujicic M., Stojanovic I., Nicoletti F., et al. Pharmacological application of carbon monoxide ameliorates islet-directed autoimmunity in mice via anti-inflammatory and anti-apoptotic effects. Diabetologia 2014, 57:980-990.
17. Zdravkovic N., Shahin A., Arsenijevic N., Lukic M.L., Mensah-Brown E.P. Regulatory T cells and ST2 signaling control diabetes induction with multiple low doses of streptozotocin. Mol. Immunol. 2009, 47:28-36.
18. Zdravkovic N., Pavlovic S., Zdravkovic V., Pejnovic N., Arsenijevic N., Lukic M.L. ST2 gene-deletion reveals a role of Foxp3+ regulatory T cells in diabetes modulation in BALB/c mice. Transl. Res. 2013, 161:118-129.
19. Petzold C., Riewaldt J., Watts D., Sparwasser T., Schallenberg S., Kretschmer K. Foxp3+ regulatory T cells in mouse models of type 1 diabetes. J. Diabetes Res. 2013, 2013:940710.
20. Brode S., Raine T., Zaccone P., Cooke A. Cyclophosphamide-induced type-1 diabetes in the NOD mouse is associated with a reduction of CD4+CD25+ Foxp3+ regulatory T cells. J. Immunol. 2006, 177:6603-6612.
21. Choi B.M., Pae H.O., Jeong Y.R., Kim Y.M., Chung H.T. Critical role of heme oxygenase-1 in Foxp3-mediated immune suppression. Biochem. Biophys. Res. Commun. 2005, 327:1066-1071.
22. Brusko T.M., Wasserfall C.H., Agarwal A., Kapturczak M.H., Atkinson M.A. An integral role for heme oxygenase-1 and carbon monoxide in maintaining peripheral tolerance by CD4+CD25+ regulatory T cells. J. Immunol. 2005, 174:5181-5186.
23. Tritt M., Sgouroudis E., d'Hennezel E., Albanese A., Piccirillo C.A. Functional waning of naturally occurring CD4+ regulatory T-cells contributes to the onset of autoimmune diabetes. Diabetes 2008, 57:113-123.
24. Lee J.H., Kang S.G., Kim C.H. FoxP3+ T cells undergo conventional first switch to lymphoid tissue homing receptors in thymus but accelerated second switch to nonlymphoid tissue homing receptors in secondary lymphoid tissues. J. Immunol. 2007, 178:301-311.
25. Ji-Won Y., Hee-Sook J. Autoimmune destruction of pancreatic β cells. Am. J. Ther. 2005, 12:580-591.
26. Macatonia S.E., Hosken N.A., Litton M., Vieira P., Hsieh C.S., Culpepper J.A., et al. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4 T cells. J. Immunol. 1995, 154:5071-5079.
27. Van Parijs L., Perez V.L., Biuckians A., Maki R.G., London C.A., Abbas A.K. Role of interleukin 12 and costimulators in T cell anergy in vivo. J. Exp. Med. 1997, 186:1119-1128.
28. Remy S., Blancou P., Tesson L., Tardif V., Brion R., Royer P.J., et al. Carbon monoxide inhibits TLR-induced dendritic cell immunogenicity. J. Immunol. 2009, 182:1877-1884.
29. Simon T., Pogu S., Tardif V., Rigaud K., Rémy S., Piaggio E., et al. Carbon monoxide-treated dendritic cells decrease β1-integrin induction on CD8+ T cells and protect from type 1 diabetes. Eur. J. Immunol. 2013, 43:209-218.
30. Pae H.O., Oh G.S., Choi B.M., Chae S.C., Kim Y.M., Chung K.R., et al. Carbon monoxide produced by heme oxygenase-1 suppresses T cell proliferation via inhibition of IL-2 production. J. Immunol. 2004, 172:4744-4751.
31. Wang G., Khattar M., Guo Z., Miyahara Y., Linkes S.P., Sun Z., et al. IL-2-deprivation and TGF-β are two non-redundant suppressor mechanisms of CD4+CD25+ regulatory T cell which jointly restrain CD4+CD25- cell activation. Immunol. Lett. 2010, 132:61-68.
32. Perruche S., Zhang P., Liu Y., Saas P., Bluestone J.A., Chen W. CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells. Nat. Med. 2008, 14:528-535.
33. Fukao T., Koyasu S. Expression of functional IL-2 receptor on mature splenic dendritic cells. Eur. J. Immunol. 2000, 30:1453-1457.
34. Sanarico N., Ciaramella A., Sacchi A., Bernasconi D., Bossu' P., Mariani F., et al. Human monocyte-derived dendritic cells differentiated in the presence of IL-2 produce proinflammatory cytokines and prime Th1 immune response. J. Leukoc. Biol. 2006, 80:555-562.
35. Rane S.G., Lee J.H., Lin H.M. Transforming growth factor-β pathway: role in pancreas development and pancreatic disease. Cytokine Growth Factor Rev. 2006, 17:107-119.
36. El-Gohary Y., Tulachan S., Wiersch J., Guo P., Welsh C., Prasadan K., et al. A smad signaling network regulates islet cell proliferation. Diabetes 2014, 63:224-236.
37. Motterlini R., Otterbein L.E. The therapeutic potential of carbon monoxide. Nat. Rev. Drug Discov. 2010, 9:728-743.
38. Otterbein L.E., Bach F.H., Alam J., Soares M., Tao L.H., Wysk M., et al. Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat. Med. 2000, 6:422-428.
39. Morse D., Pischke S.E., Zhou Z., Davis R.J., Flavell R.A., Loop T., et al. Suppression of inflammatory cytokine production by carbon monoxide involves the JNK pathway and AP-1. J. Biol. Chem. 2003, 278:36993-36998.
40. Schallner N., Romaio C.C., Biermann J., Lagre'ze W.A., Otterbein L.E., Buerkle H., et al. Carbon monoxide abrogates ischemic insult to neuronal cells via the soluble guanylate cyclase-cGMP pathway. PLOS ONE 2013, 8:e60672.
41. Hou S., Xu R., Heinemann S.H., Hoshi T. The RCK1 high-affinity Ca2+ sensor confers carbon monoxide sensitivity to Slo1 BK channels. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:4039-4043.